FDA OKs PML Risk Test for Patients on Tysabri
(MedPage Today) — The FDA has approved the first test for assessing the risk of progressive multifocal leukoencephalopathy in patients on natalizumab (Tysabri).
(MedPage Today) — The FDA has approved the first test for assessing the risk of progressive multifocal leukoencephalopathy in patients on natalizumab (Tysabri).
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.